Erythropoietin may improve anemia in patients with autoimmune hemolytic anemia associated with reticulocytopenia. (se deschide o fereastră nouă)

Arbach O, Funck R, Seibt F, Salama A.

Sursă‎: Transfus Med Hemother 2012;39(3):221-3.

Index‎: PubMed 22851939

DOI‎: 10.1159/000339260

https://www.ncbi.nlm.nih.gov/pubmed/22851939 (se deschide o fereastră nouă)

The changing spectrum of drug-induced immune hemolytic anemia. (se deschide o fereastră nouă)

Arndt PA, Garratty G.

Sursă‎: Semin Hematol 2005;42(3):137-44.

Index‎: PubMed 16041663

https://www.ncbi.nlm.nih.gov/pubmed/16041663 (se deschide o fereastră nouă)

Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. (se deschide o fereastră nouă)

Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, Fattizzo B, Consonni D, Cortelezzi A, Fanin R, Zanella A.

Sursă‎: Blood 2012;119(16):3691-7.

Index‎: PubMed 22267606

DOI‎: 10.1182/blood-2011-06-363556

https://www.ncbi.nlm.nih.gov/pubmed/22267606 (se deschide o fereastră nouă)

Autoimmune hemolytic anemia. (se deschide o fereastră nouă)

Gehrs BC, Friedberg RC.

Sursă‎: Am J Hematol 2002;69(4):258-71.

Index‎: PubMed 11921020

https://www.ncbi.nlm.nih.gov/pubmed/11921020 (se deschide o fereastră nouă)

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. (se deschide o fereastră nouă)

Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC.

Sursă‎: Blood 2010;116(23):4783-5.

Index‎: PubMed 20841509

DOI‎: 10.1182/blood-2010-06-291831

https://www.ncbi.nlm.nih.gov/pubmed/20841509 (se deschide o fereastră nouă)

A case of late-onset systemic lupus erythematosus with severe anemia. (se deschide o fereastră nouă)

Matsumoto M, Kaieda S, Honda S, Ida H, Hoshino T, Fukuda T.

Sursă‎: Kurume Med J 2013;60(1):25-8.

Index‎: PubMed 23925156

https://www.ncbi.nlm.nih.gov/pubmed/23925156 (se deschide o fereastră nouă)

High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. (se deschide o fereastră nouă)

Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA.

Sursă‎: Blood 2002;100(2):704-6.

Index‎: PubMed 12091370

DOI‎: 10.1182/blood-2002-01-0087

https://www.ncbi.nlm.nih.gov/pubmed/12091370 (se deschide o fereastră nouă)

Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. (se deschide o fereastră nouă)

Zecca M, De Stefano P, Nobili B, Locatelli F.

Sursă‎: Blood 2001;97(12):3995-7.

Index‎: PubMed 11389047

https://www.ncbi.nlm.nih.gov/pubmed/11389047 (se deschide o fereastră nouă)

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. (se deschide o fereastră nouă)

Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F.

Sursă‎: Blood 2003;101(10):3857-61.

Index‎: PubMed 12531800

DOI‎: 10.1182/blood-2002-11-3547

https://www.ncbi.nlm.nih.gov/pubmed/12531800 (se deschide o fereastră nouă)